RxDoctor Payments Data

Jameson Estes, MD

Family Medicine · Locust Grove, GANPI 1265567796

Payments from drug & device makers

$9,257in general payments, 2019–2025

Across 627 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • AbbVie$979
  • GSK$603
  • Astellas Pharma US Inc$588
  • Pfizer$448
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$9,15199%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca64$1,102
Novo Nordisk86$1,010
AbbVie(2 entities)85$979
GSK39$603
Astellas Pharma US Inc30$588
Pfizer30$448
Bayer48$437
Amgen(2 entities)24$390
Novartis21$381
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$329
Lilly USA, LLC19$313
Upsher-smith Laboratories LLC16$218
Amarin Pharma, Inc.8$184
Eisai Inc.9$147
Supernus Pharmaceuticals, Inc.13$146
Grifols USA, LLC8$125
Corium, LLC5$124
Boehringer Ingelheim8$123
Merck8$122
Johnson & Johnson8$120
Jazz Pharmaceuticals Inc.6$107
Otsuka America Pharmaceutical, Inc.5$100
Teva Pharmaceuticals USA, Inc.6$94
Takeda Pharmaceuticals U.S.A., Inc.5$84
Regeneron Healthcare Solutions, Inc.3$65
Biohaven Pharmaceuticals, Inc.3$60
Biohaven Pharmaceutical Holding Company Ltd.3$56
Dexcom, Inc.3$53
Genentech USA, Inc.3$44
Vanda Pharmaceuticals Inc.3$44
Idorsia Pharmaceuticals US Inc3$43
Currax Pharmaceuticals LLC3$42
Verity Pharmaceuticals Inc.2$40
Axsome Therapeutics, Inc.2$40
Bausch Health US, LLC2$40
Sanofi-aventis U.S. LLC2$33
Lundbeck LLC2$32
Exact Sciences2$30
Phadia US Inc.2$29
Adlon Therapeutics L.p.2$27
Corcept Therapeutics1$27
Arbor Pharmaceuticals, Inc.2$26
Shield Therapeutics Inc1$25
Nalpropion Pharmaceuticals LLC2$24
Sunovion Pharmaceuticals Inc.1$22
Melinta Therapeutics, LLC1$21
Phathom Pharmaceuticals, Inc.1$21
Xeris Pharmaceuticals, Inc.1$20
Hikma Pharmaceuticals USA1$18
Mylan Specialty L.p.1$18
Shire North American Group Inc1$16
Sanofi Pasteur Inc.1$15
Scynexis, Inc.1$15
Acerus Pharmaceuticals Corporation1$13
Dermira, Inc.1$12
Cardiovascular Systems Inc.1$12

How this compares

$9,257 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$131,448
Medicare patients
372
Services billed
2,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide260$299,681
FarxigaDapagliflozin Propanediol152$150,531
MounjaroTirzepatide124$138,313
Trelegy ElliptaFluticasone/Umeclidin/Vilanter133$103,540
EliquisApixaban91$88,420
JardianceEmpagliflozin68$66,541
Dupixent SyringeDupilumab14$54,842
OtezlaApremilast11$54,108
JanuviaSitagliptin Phosphate37$41,007
LinzessLinaclotide47$35,180
XareltoRivaroxaban34$30,490
TrulicityDulaglutide16$28,209
Invega SustennaPaliperidone Palmitate12$26,639
EntrestoSacubitril/Valsartan25$22,240
TradjentaLinagliptin13$20,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,010$314,889272 claims
Lilly USA, LLCMounjaro, Trulicity$313$166,522140 claims
AstraZenecaFarxiga, Symbicort$1,102$159,501181 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$603$122,623191 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$123$98,42597 claims
PfizerEliquis$448$88,42091 claims
MerckJanuvia, Janumet$122$57,28755 claims
Johnson & JohnsonXarelto, Invega Sustenna$120$57,12946 claims
AmgenOtezla$390$54,10811 claims
AbbVieLinzess, Qulipta$979$52,76662 claims
NovartisEntresto$381$22,24025 claims
BayerKerendia$437$14,95914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Locust Grove

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →